HUTCHMED, AstraZeneca file US NDA for Orpathys plus Tagrisso in MET-driven lung cancerSep 29Regulatory decisionAstraZenecaHutchmed
HUTCHMED details ESMO 2026 slots for SAFFRON, SANOVO Phase III lung cancer dataSep 24PublicationAstraZenecaHutchmed
BlossomHill reports 45% response rate for BH-30643 in EGFR C797S lung cancerSep 15Clinical readoutBH-30643BlossomHill Therapeutics
HUTCHMED and AstraZeneca report positive Phase III SAFFRON data in EGFR-mutated lung cancerAug 17Clinical readoutAstraZenecaHutchmed
Nuvectis reports Q2 2026 results as ciprocopan wins first China approvalAug 4Quarterly updateNuvectis Pharma, Inc.
AstraZeneca posts PASSAGE Phase 4 tezepelumab results; registers new prostate, lung, and NF2 trialsJul 17Weekly roundup, 6 itemsAstraZenecaosimertinib
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin
Sign inSign in